Survodutide

evidence score

fat loss

Research Only

148 studies

BI 456906GLP-1 glucagon dual agonist

Survodutide is an investigational once-weekly dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase II trials demonstrated ~19% weight loss at 46 weeks. Currently in Phase III for obesity and metabolic dysfunction- associated steatohepatitis (MASH/NASH). Glucagon co-agonism provides additional hepatic fat reduction beyond GLP-1 alone, making it particularly relevant for fatty liver disease. Not available outside clinical trials.

Evidence

Strong evidence

Safety

Unknown safety profile

Clinical Status

Phase III

Research Sync

Feb 19, 2026

Dosing

Typical

4.8 mg

0.3 mgRange9.6 mg

FrequencyOnce weekly subcutaneous (trial doses)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~7 days (estimated)

OnsetWeeks for weight loss; appetite suppression within days

DurationOngoing; effects reverse after discontinuation

Routes

subcutaneous

Evidence Score

Level A — Strong

148 studies indexed · 8 meta-analyses

Scoring Factors

Volume(40%)~43/100

Quality(30%)~54/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Survodutide is currently categorized as a fat loss compound.

Evidence is strong (77/100) with a relatively mature body of research (148 indexed studies).

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Dual GLP-1/glucagon receptor agonist; adds hepatic fat mobilization and increased energy expenditure to GLP-1 satiety effects

Practical Context

Strongest current signals

Level A: Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Level A: Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
Level B: Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Elevated caution signals

1 severe/high side effect flag